Carfilzomib increased survival rate in relapsed multiple myeloma

5 Dec 2015

Results of a recent study showed that patients treated with carfilzomib plus dexamethasone achieved progression-free survival of 18.7 months compared to 9.4 months in those receiving bortezomib plus dexamethasone, a current standard of care in relapsed multiple myeloma.

These findings come from the phase 3 head-to-head ENDEAVOR study comparing carfilzomib (marketed as Kyprolis) plus dexamethasone to bortezomib (marketed as Velcade) plus dexamethasone in patients with relapsed multiple myeloma.

The results demonstrate that patients with relapsed multiple myeloma treated with carfilzomib lived twice as long without disease worsening as those treated with bortezomib.


Clinically meaningful results

“For patients with multiple myeloma, these results are clinically meaningful and translate to more than nine months without disease progression.” said study co-author and investigator, Meletios A. Dimopoulos, M.D., professor of Clinical Therapeutics at the National and Kapodistrian University of Athens, School of Medicine.

The most common adverse events (greater than 25%) in the carfilzomib arm were diarrhea, anemia, fatigue, dyspnea, pyrexia, and insomnia. Treatment discontinuation due to adverse events and on-study deaths were comparable between the two arms.

Source: eCancer News

Login to your account

Did you forget your password?